Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study
Headache: The Journal of Head and Face Pain · 2023
DOI: 10.1111/head.14636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2023. Verfasst von Victor S Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Dihydroergotamine, Cardiovascular Diseases, Vasoconstrictor Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Impel Pharmaceuticals, Inc..
Abstract (Originalsprache)
Background
Dihydroergotamine (DHE), like triptans, is contraindicated in patients with ischemic heart disease or coronary vasospasm. Its true safety, tolerability, and efficacy in patients with cardiovascular risk without ischemic heart disease or coronary vasospasm remain unclear.
Objectives
To assess the safety, tolerability, and effectiveness of repetitive intravenous DHE in patients with cardiovascular risk factors.
Methods
A single‐center, retrospective cohort study was conducted at the Jefferson Headache Center inpatient unit for refractory chronic migraine patients treated with our intravenous DHE protocol between January 1, 2019, and October 15, 2019. We evaluated tolerability and effectiveness outcomes based on atherosclerotic cardiovascular disease 10‐year calculated risk scores, stratified into low (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Thomas Jefferson University College of Population Health, Philadelphia, Pennsylvania, USA.
- Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Impel Pharmaceuticals Inc., Seattle, Washington, USA.
ORCID-Profile: Victor S Wang, Clinton Lauritsen, Sheena K Aurora
Förderung
- Impel Pharmaceuticals, Inc.
Zitieren
APA
Wang, V. S., Kosman, J., Yuan, H., Lauritsen, C., Shrewsbury, S., Aurora, S. K., Hopkins, M., & Silberstein, S. (2023). Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14636
Vancouver
Wang VS, Kosman J, Yuan H, Lauritsen C, Shrewsbury S, Aurora SK, et al. Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14636
BibTeX
@article{Wang2023,
author = {Wang, Victor S and Kosman, Justin and Yuan, Hsiangkuo and Lauritsen, Clinton and Shrewsbury, Stephen and Aurora, Sheena K and Hopkins, Mary and Silberstein, Stephen},
title = {Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study},
journal = {Headache: The Journal of Head and Face Pain},
year = {2023},
doi = {10.1111/head.14636}
}
EUVIMED